Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update

$29.1 million in cash and cash equivalents as of March 31, 2023; $15 million registered direct offering in May 2023 extends runway through May 2024
Halo-Lido Phase 2b trial completed with topline... | June 14, 2023

Related Keywords

New Jersey ,United States ,India ,Ilanit Allen ,Leonard Mazur ,Greg Salsburg ,Company Nasdaq ,Exchange Commission ,Development Rd Expenses ,Citius Pharmaceuticals Inc ,Jersey Technology Business Tax Certificate Transfer Program ,Securities Exchange ,Prnewswire Citius Pharmaceuticals Inc ,Lido Phase ,Halo Lido Phase ,Mino Lok Phase ,Citius Pharmaceuticals ,Fast Track ,Securities Act ,Securities Exchange Act ,Annual Report ,Tables Follow ,Loss Per Share ,Flows From Operating Activities ,Flows From Financing Activities ,Cash Equivalents ,